Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Enrollment complete in pivotal study of oral testosterone replacement therapy

May 3, 2012

E.U. grant issued to support development of drug for fetal growth restriction

May 2, 2012

FDA approves new therapy for type 1 Gaucher's disease

May 2, 2012

FDA accepts lomitapide NDA for review

May 2, 2012

New diacylglycerol O-acyltransferase 1 inhibitors designed

May 2, 2012

Trimel gives update on special population study of male hypogonadism treatment

April 30, 2012

FDA approves new product to treat erectile dysfunction

April 30, 2012

Proximagen designs novel chemokine CCR2 receptor antagonists

April 30, 2012

Shionogi submits NDA for tablets to treat vulvar and vaginal atrophy

April 30, 2012

Omthera Pharmaceuticals reports topline results from EVOLVE study

April 27, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...